Treatment of anemia by recombinant human erythropoietin in cancer patients undergoing radiotherapy

Simple item page
dc.contributor.authorYurut-Caloglu, Vuslat
dc.contributor.authorCaloglu, Murat
dc.date.accessioned2024-06-12T10:51:39Z
dc.date.available2024-06-12T10:51:39Z
dc.date.issued2008
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAnemia is a deficiency in red blood cells or in the hemoglobin (Hb) levels that leads to a decrease in the transport capacity of oxygen in the blood, which can reduce tolerance in radiotherapy (RT) and chemotherapy. The relationship between anemia and hypoxia, however, is complex and influenced by multiple variables. Although the blood Hb values that might develop hypoxia in tumors were not described clearly, optimal oxygen pressure was accepted in patients with an Hb value of 12-14 g/dL. Erythropoietin is a glycoprotein, which acts via EPOR to stimulate the growth, to prevent apoptosis, and to induce differentiation of red blood cell precursors. RhuEPO-alpha and -beta are classically administered subcutaneously three times per week at doses ranging from 150 to 300 IU/kg. Darbepoetin-alpha has been shown to exhibit a longer elimination half-life, thus allowing a once-weekly administration at the dose of 2.25 mu g/kg. Side-effects related to rhuEPO include hypertension and thromboembolic events. RhuEPO can be used effectively in the treatment of anemia in patients with solid tumor being treated by RT or chemoradiotherapy. Furthermore, the use of rhuEPO has been demonstrated to have a sustained beneficial impact on quality of life in cancer patients. However, the role of combination of rhuEPO with external RT still remains inconclusive and several clinical trials have been pointed increased mortality in patients treated with rhuEPO. In this paper, the probable radiobiological effects of anemia in patients treated with RT, the beneficial and adverse effects of rhuEPO, and related studies are reviewed. Future directions for the use of rhuEPO are proposed.en_US
dc.identifier.doi10.1111/j.1743-7563.2008.00217.x
dc.identifier.endpage207en_US
dc.identifier.issn1743-7555
dc.identifier.issn1743-7563
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-57849107619en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage199en_US
dc.identifier.urihttps://doi.org/10.1111/j.1743-7563.2008.00217.x
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18441
dc.identifier.volume4en_US
dc.identifier.wosWOS:000261637200003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofAsia-Pacific Journal Of Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnemiaen_US
dc.subjectCanceren_US
dc.subjectErythropoietinen_US
dc.subjectHypoxiaen_US
dc.subjectRadiotherapyen_US
dc.subjectChemotherapy-Induced Anemiaen_US
dc.subjectQuality-Of-Lifeen_US
dc.subjectRadiation-Therapyen_US
dc.subjectEpoetin-Alphaen_US
dc.subjectCervical-Carcinomaen_US
dc.subjectHemoglobin Levelsen_US
dc.subjectDouble-Blinden_US
dc.subjectConcurrent Chemoradiotherapyen_US
dc.subjectIncreases Hemoglobinen_US
dc.subjectReceptor Expressionen_US
dc.titleTreatment of anemia by recombinant human erythropoietin in cancer patients undergoing radiotherapyen_US
dc.typeArticleen_US

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize